According to the Chengdu Pilot's announcement, the company's wholly-owned subsidiary in Hong Kong previously obtained 29.55% of the shares in innovative pharmaceutical company Connexus Therapeutics using intangible assets worth 126 million yuan. After Connexus initiated additional financing, the related party Aludel Ltd increased its capital by 1.5 million US dollars and obtained 2.3% of its shares. After the capital increase was completed, the company's shareholding ratio fell to 28.9%, and the company's investment in Connexus passively formed a joint investment with related parties. This transaction does not constitute a major asset restructuring. It has been reviewed and approved by the company's board of directors, and still needs to be submitted to the shareholders' meeting for review.

According to the Chengdu Pilot's announcement, the company's wholly-owned subsidiary in Hong Kong previously obtained 29.55% of the shares in innovative pharmaceutical company Connexus Therapeutics using intangible assets worth 126 million yuan. After Connexus initiated additional financing, the related party Aludel Ltd increased its capital by 1.5 million US dollars and obtained 2.3% of its shares. After the capital increase was completed, the company's shareholding ratio fell to 28.9%, and the company's investment in Connexus passively formed a joint investment with related parties. This transaction does not constitute a major asset restructuring. It has been reviewed and approved by the company's board of directors, and still needs to be submitted to the shareholders' meeting for review.